FDA Approves Telix’s Pixclara to Distinguish Glioma Recurrence or Progression From Treatment Effects

Key Facts

The US Food and Drug Administration approved Telix Pharmaceuticals’ Pixclara on September 14, 2026. The radioactive diagnostic drug is used with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, alongside other diagnostic evaluations.

Telix said Pixclara is the first FDA-approved FET-PET imaging drug for glioma in the United States. The indication covers adults and pediatric patients aged 1 month and older, making the authorization narrower than general brain-cancer imaging.

The drug’s generic name is floretyrosine F 18, a radiolabeled derivative of the amino acid tyrosine. It accumulates in cells expressing the amino-acid transporters LAT1 and LAT2, while fluorine-18 emissions allow the signal to be detected by a PET scanner.

Effectiveness was evaluated in 2 studies: a prospective, open-label, single-center study involving 127 patients and a blinded central-read study that retrospectively analyzed images from 254 patients in multicenter clinical practice. Pixclara readings were compared with a composite reference based on available clinical, imaging and pathology evidence.

The approved label sets important limits on interpretation: a positive image does not by itself confirm recurrence or progression, and a negative image does not rule it out. Results should therefore be correlated with histopathology, cross-sectional imaging and clinical history when decisions are made.

Safety was evaluated in 382 patients with glioma. The most commonly reported adverse reaction with an incidence of at least 0.5% was headache, which occurred in 0.5%. The label also warns that the drug adds to cumulative radiation exposure, requiring safe handling, hydration and frequent urination after administration.

For Telix, the approval turns Pixclara from a development asset into an approved US diagnostic product and expands its precision-medicine portfolio. However, the approval announcement gave no launch date, price or sales forecast, so the immediate revenue impact cannot be quantified from the published information.

Telix is also pursuing a Phase 3 registrational study for a potential indication expansion into brain-metastasis diagnosis. Unless new data support and regulators authorize that expansion, the current US use remains limited to the approved glioma indication.